Genmab sales of Darzalex exceed expectations in Q3

Third quarter sales figures for Darzalex, which Genmab has in-licensed to Johnson & Johnson, are far better than previous estimates.
Photo: Joost Melis / Genmab / PR
Photo: Joost Melis / Genmab / PR
BY MARKETWIRE, TRANSLATED BY DANIEL PEDERSEN

The Genmab-developed treatment for multiple myeloma, a type of bone marrow cancer, has exceeded expectations in the third quarter of the year, according to Q3 reports from Johnson & Johson, which obtained the drug through an in-licensing agreement.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading